GleamWall
中文EN

AVLN Avalyn Pharma Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1540171 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets7.3%
Debt / equity0.04x
Current ratio25.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue——————
R&D expense$25.49M$24.73M$22.89M$22.09M$17.88M$15.32M
SG&A expense$7.60M$6.56M$5.02M$3.23M$3.90M$3.40M
Operating income-$33.09M-$31.29M-$27.91M-$25.32M-$21.78M-$18.72M
Interest expense$277,000$272,000$98,000$1,000$0$0
Income tax$0$0$0$0$0$0
Net income-$29.66M-$28.93M-$26.87M-$23.58M-$20.19M-$17.50M
EBITDA-$32.99M-$31.18M-$27.85M-$25.31M-$21.77M-$18.71M
EPS (basic)-0.67-0.98-21.83-20.34-17.63-63.24
EPS (diluted)-0.67-0.98-21.83-20.34-17.63-63.24
Weighted avg. shares (diluted)44.35M29.65M1.23M1.16M1.15M276,792
Balance sheet
Cash & equivalents$145.42M$264.20M$92.31M$27.57M$61.30M$28.80M
Short-term investments$182.03M$88.23M$30.82M———
Current assets$333.71M$357.99M$129.99M———
PP&E, net$1.17M$1.21M$1.26M———
Total assets$399.30M$425.45M$135.66M———
Current liabilities$12.96M$10.81M$11.79M———
Long-term debt$14.82M$14.80M$14.81M———
Total debt$14.82M$14.80M$14.81M———
Total liabilities$29.05M$27.10M$27.69M———
Shareholders' equity$370.25M$398.35M-$264.25M-$215.56M-$194.39M-$191.57M
Net debt-$130.61M-$249.40M-$77.50M———
Shares outstanding44.39M44.33M1.23M———
Cash flow statement
Operating cash flow-$26.27M-$26.08M-$29.89M-$17.31M-$20.70M-$19.27M
Capital expenditure$72,000$269,000$318,000$84,000$0$8,000
Free cash flow-$26.34M-$26.34M-$30.21M-$17.39M-$20.70M-$19.28M
Investing cash flow-$91.77M-$118.71M$55.02M-$26.32M-$36.69M$24.12M
Financing cash flow-$733,000$316.67M$14.86M$9.90M$89.88M$0
Depreciation & amortization$104,400$110,000$63,000$9,000$9,000$10,000
Stock-based compensation$3.10M$2.79M$1.19M$725,000$1.13M$543,000

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.